AUTHOR=Gonzaga Aitor , Andreu Etelvina , Hernández-Blasco Luis M. , Meseguer Rut , Al-Akioui-Sanz Karima , Soria-Juan Bárbara , Sanjuan-Gimenez Jose Carlos , Ferreras Cristina , Tejedo Juan R. , Lopez-Lluch Guillermo , Goterris Rosa , Maciá Loreto , Sempere-Ortells Jose M. , Hmadcha Abdelkrim , Borobia Alberto , Vicario Jose L. , Bonora Ana , Aguilar-Gallardo Cristobal , Poveda Jose L. , Arbona Cristina , Alenda Cristina , Tarín Fabian , Marco Francisco M. , Merino Esperanza , Jaime Francisco , Ferreres José , Figueira Juan Carlos , Cañada-Illana Carlos , Querol Sergio , Guerreiro Manuel , Eguizabal Cristina , Martín-Quirós Alejandro , Robles-Marhuenda Ángel , Pérez-Martínez Antonio , Solano Carlos , Soria Bernat TITLE=Rationale for combined therapies in severe-to-critical COVID-19 patients JOURNAL=Frontiers in Immunology VOLUME=14 YEAR=2023 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1232472 DOI=10.3389/fimmu.2023.1232472 ISSN=1664-3224 ABSTRACT=

An unprecedented global social and economic impact as well as a significant number of fatalities have been brought on by the coronavirus disease 2019 (COVID-19), produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute SARS-CoV-2 infection can, in certain situations, cause immunological abnormalities, leading to an anomalous innate and adaptive immune response. While most patients only experience mild symptoms and recover without the need for mechanical ventilation, a substantial percentage of those who are affected develop severe respiratory illness, which can be fatal. The absence of effective therapies when disease progresses to a very severe condition coupled with the incomplete understanding of COVID-19’s pathogenesis triggers the need to develop innovative therapeutic approaches for patients at high risk of mortality. As a result, we investigate the potential contribution of promising combinatorial cell therapy to prevent death in critical patients.